Head-to-Head biologic battle for Sight-Threatening eye inflammation
NCT ID NCT02929251
First seen Nov 01, 2025 · Last updated Apr 28, 2026 · Updated 27 times
Summary
This study tested three different biologic drugs (adalimumab, anakinra, and tocilizumab) in 112 people with severe, hard-to-treat eye inflammation called uveitis. The goal was to see which drug works best to reduce eye inflammation and allow patients to lower their steroid use. Uveitis can cause blindness if not controlled, and standard treatments often fail. The trial aimed to find the most effective biologic option for these patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UVEITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHNO des Quinze Vingt
Paris, France
-
CHNO des Quinze Vingt - Médecine interne
Paris, France
-
CHNO des Quinze Vingt - Ophtalmologie
Paris, France
-
CHRU de Nancy
Nancy, France
-
CHRU de Nancy - Médecine interne
Nancy, France
-
CHRU de Rennes Hopital Sud Médecine interne
Rennes, France
-
CHU Clermont-Ferrand - Hopital Gabriel Montpied - Médecine interne
Clermont-Ferrand, France
-
CHU Clermont-Ferrand - Hopital Gabriel Montpied - Ophtalmologie
Clermont-Ferrand, France
-
CHU Dijon Bourgogne -Ophtalmologie
Dijon, France
-
CHU Dijon Bourgogne Médecine Interne et Maladies Systémiques - Médecine 2 / SOC 2
Dijon, France
-
CHU Rennes - Hopital Ponchaillou - Ophtalmologie
Rennes, France
-
CHU Rouen - Hopital Charles Nicolle - Médecine interne
Rougé, France
-
CHU Rouen - Hopital Charles Nicolle - Ophtalmologie
Rouen, France
-
CHU TOULOUSE - HOPITAL PIERRE PAUL RIQUET - Ophtalmologie
Toulouse, France
-
CHU Toulouse - Hopital Rangueil
Toulouse, France
-
HCL - Hôpital de la Croix Rousse - Médecine interne
Lyon, France
-
HCL - Hôpital de la Croix Rousse - Ophtalmologie
Lyon, France
-
Hopital Avicenne - CRC
Bobigny, France
-
Hopital Avicenne - Ophtalmologie
Bobigny, France
-
Hopital Avicenne- Médecine interne
Bobigny, France
-
Hopital Pellegrin
Bordeaux, France
-
Hopital Pitié Salpetriere
Paris, France
-
Hopital Rotchild - Médecine interne
Paris, France
-
Hopital Rotchild - Ophtalmologie
Paris, France
-
Hopital Saint André - Médecine interne
Bordeaux, France
-
Hopital la pitié salpetriere - Médecine interne 1
Paris, paris, 75013, France
-
Hôpital de la pitié salpêtrière - Ophtalmologie
Paris, France
Conditions
Explore the condition pages connected to this study.